Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Expert Insights on Generics and Biosimilars

With health reform on the horizon, generics and biosimilars are at the forefront of the discussion. Will the US establish a pathway for these drugs? What are the hurdles?

Get expert insights on:

  • Future role of generic companies as pharma faces unprecedented patent expiration on blockbuster compounds
  • Manufacturing and regulatory hurdles for biosimilars
  • Role of CROs in the generics industry
  • Competitive pressure from generic manufacturers in India and China
Engage an Expert on Generics and Biosimilars

Gerson Lehrman Group Council Members are available to discuss Generics and Biosimilars via phone consultations, live meetings, surveys, and other custom GLG products and services.

Find, engage, and manageSM experts today through the GLG platform

Featured Council Members

GLG Council Members are leading experts including academics, scientists, and industry specialists

Bret Koplow, Partner, Head of Food & Drug Practice, SONNENSCHEIN, NATH & ROSENTHAL, LLP

Bret KoplowWhat is a GLG Educator?|GLG Educators have qualified for GLG Member Programs and are therefore eligible to participate in ongoing in-depth consulting projects with GLG clients.What is a Premium Council Partner?|Premium Council Partners are leading Professional Service Firms that work exclusively with GLG.

Partner, Head of Food & Drug PracticeSONNENSCHEIN, NATH & ROSENTHAL, LLP

Joe Renner, MBA, CEO and part owner, ZYDUS PHARMACEUTICALS USA INC

Joe Renner, MBAWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

CEO and part ownerZYDUS PHARMACEUTICALS USA INC

Kurt Orlofski, President and COO, G & W Laboratories Inc

Kurt OrlofskiWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

President and COOG & W Laboratories Inc

Dea Belazi, PharmD, MPH, PAHM, Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM

Dea Belazi, PharmD, MPH, PAHMWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Pharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Browse all 410 Leading Experts

Study Groups

Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry

Study Group Name No. Members
U.S. Department of Agriculture Experts: Legal, Economic, and Regulatory Affairs 28
Neurologists who Treat West Syndrome (Infantile Spasms) (US) 25
Parkinson's Disease Neurologists (US) 101
Rebif Prescribers for Multiple Sclerosis (US) 13
Zanaflex Prescribers for Spasticity (US) 37

Browse all 974 Study Groups

Recent News Analyses

News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations

2 generic drugs - Imitrex and Eloxatin

August 16, 2009

GLG Expert Contributor

Sun Pharma gets US nod for two generic drugs | economictimes.indiatimes.com

I do not have a problem with a generic-like Imitrex. I do for Eloxatin. Generics can be up to 20% off, so for migraine med, that is more acceptable than a cancer treatment.

Browse all 7669 GLG News Analyses

Contact Gerson Lehrman Group to engage a Generics and Biosimilars expert